Cancer Topics Index 05/03/2016(Daily Test version/ 日刊テスト版)No.22

Cancer Topics Index 05/03/2016(Daily Test version/ 日刊テスト版) No.22

Flags 【海外:overseas】
21 studies found for: cancer | received from 04/19/2016 to 04/19/2016

1 Not yet recruiting
Breast Cancer WEight Loss Study (BWEL Study)
Conditions: Ductal Breast Carcinoma in Situ; Breast Carcinoma
Interventions: Other: Health Education Program; Other: Weight Loss Intervention
Sponsor:Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:NCT02750826

2 Recruiting
68Ga-NOTA-BBN-RGD PET/CT in Prostate Cancer Patients
Condition: Prostate Cancer
Intervention: Drug: 68Ga-NOTA-BBN-RGD
Sponsor:Peking Union Medical College Hospital
ClinicalTrials.gov Identifier:NCT02747290

3 Recruiting
PET Imaging of Patients With Cancer Using 124I-PU-AD
Conditions: Solid Malignancy; Lymphoma; Multiple Myeloma
Interventions: Drug: 124I-PU-AD; Device: PET Scan; Other: Blood draws
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02751554

4 Not yet recruiting
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Abemaciclib; Drug: Tamoxifen; Drug: Prophylactic Loperamide
Sponsor:Eli Lilly and Company
ClinicalTrials.gov Identifier:NCT02747004

5 Not yet recruiting
Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination
Condition: Prostate Cancer
Intervention: Other: Blood test (PSA)
Sponsor:Kaplan Medical Center
ClinicalTrials.gov Identifier:NCT02747563

6 Recruiting
Experiential Training With Healthcare Coaching in Childhood Cancer Patients
Conditions: Child; Neoplasms
Interventions: Behavioral: healthcare professional coaching; Behavioral: Placebo Control
Sponsor:The University of Hong Kong
ClinicalTrials.gov Identifier:NCT02754973

7 Recruiting
uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
Conditions: Non-small Cell Lung Cancer; Malignant Pleural Mesothelioma; Large Cell Neuroendocrine Carcinoma of the Lung
Intervention: Other: 68Ga-NOTA-AE105 PET/CT
Sponsor:Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:NCT02755675

8 Not yet recruiting
Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
Conditions: Metastatic Melanoma; Stage III Mucosal Melanoma of the Head and Neck; Stage IIIA Skin Melanoma; Stage IIIB Skin Melanoma; Stage IIIC Skin Melanoma; Stage IV Skin Melanoma; Stage IVA Mucosal Melanoma of the Head and Neck; Stage IVB Mucosal Melanoma of the Head and Neck; Stage IVC Mucosal Melanoma of the Head and Neck
Interventions: Biological: Aldesleukin; Other: Laboratory Biomarker Analysis; Biological: Pembrolizumab
Sponsor:Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:NCT02748564

9 Not yet recruiting
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
Conditions: Astrocytoma; Glioma; Oligodendroglioma
Interventions: Biological: Hepatitis A Vaccine; Other: Laboratory Biomarker Analysis; Biological: Tetanus Toxoid Vaccine; Biological: Trivalent Influenza Vaccine
Sponsor:Comprehensive Cancer Center of Wake Forest University
ClinicalTrials.gov Identifier:NCT02747407

10 Not yet recruiting
Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors
Conditions: Adrenal Cortex Neoplasms; Adrenal Cortex Diseases
Sponsor:Bnai Zion Medical Center
ClinicalTrials.gov Identifier:NCT02747355

11 Not yet recruiting
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Condition: Pediatric Solid Tumors
Interventions: Drug: Sorafenib; Drug: Irinotecan
Sponsor:Washington University School of Medicine
ClinicalTrials.gov Identifier:NCT02747537

12 Not yet recruiting
A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
Condition: Malignant Non-small Cell Neoplasm of Lung Stage IV
Intervention: Drug: Capmatinib (INC280)
Sponsor:Massachusetts General Hospital
ClinicalTrials.gov Identifier:NCT02750215

13 Not yet recruiting
A Trial of SHR3680 in mCRPC
Condition: Neoplasm
Intervention: Drug: SHR3680 oral administration
Sponsor:Jiangsu HengRui Medicine Co., Ltd.
ClinicalTrials.gov Identifier:NCT02747342

14 Not yet recruiting
eRAPID Feasibility Pilot Study in Pelvic Radiotherapy
Condition: Cancer
Intervention: Device: eRAPID
Sponsor:University of Leeds
ClinicalTrials.gov Identifier:NCT02747264

15 Recruiting
Determination of Immune Phenotype in Glioblastoma Patients
Condition: Glioblastoma Multiforme
Intervention: Procedure: Surgery
Sponsor:University of Ulm
ClinicalTrials.gov Identifier:NCT02751138

17 Not yet recruiting
Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders
Conditions: Lung Transplant; Lung Resection; Lung Cancer; Asthma; Cystic Fibrosis; Chronic Obstructive Pulmonary Disease; Emphysema; Mesothelioma; Asbestosis; Pulmonary Embolism; Interstitial Lung Disease; Pulmonary Fibrosis; Bronchiectasis; Seasonal Allergies; Cold Virus; Lung Infection; Pulmonary Hypertension; Pulmonary Dysplasia; Obstructive Sleep Apnea
Interventions: Drug: HP 3He; Drug: HP 129Xe; Drug: PFP; Drug: SF6; Device: 129Xe Small and Large Human Lung Coil; Device: 3He Human Lung Coil; Device: PFP and SF6 Human Lung Coil
Sponsor:Thunder Bay Regional Research Institute
ClinicalTrials.gov Identifier:NCT02748798

18 Not yet recruiting
The Clinical Relevance of Margins in Frameless Stereotactic Radiosurgery for Intact Brain Metastases: a Randomized Trial of 0 vs 2 mm Margins
Condition: Brain Metastases
Intervention: Procedure: Stereotactic Radiosurgery
Sponsor:University of Chicago
ClinicalTrials.gov Identifier:NCT02747303

20 Recruiting
Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Condition: Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Nivolumab; Drug: Albumin-bound paclitaxel; Drug: Paricalcitol; Drug: Cisplatin; Drug: Gemcitabine
Sponsor:HonorHealth Research Institute
ClinicalTrials.gov Identifier:NCT02754726

【びまん性大細胞型B 細胞リンパ腫】
23 Recruiting
Chidamide Plus R-CHOP in Elderly DLBCL
Condition: Diffuse Large B-cell Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Epirubicin; Drug: Vincristine; Drug: Prednisone; Drug: Chidamide
Sponsor:Ruijin Hospital
ClinicalTrials.gov Identifier:NCT02753647

24 Recruiting
Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma
Condition: Peripheral T Cell Lymphoma
Intervention: Drug: Chidamide
Sponsor:Ruijin Hospital
ClinicalTrials.gov Identifier:NCT02753543

25 Not yet recruiting
Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab
Condition: Lymphoma, Non-Hodgkin
Interventions: Drug: ABP 798; Drug: Rituximab
ClinicalTrials.gov Identifier:NCT02747043

◇EU, EMA, CHMP, Cancer Research UK, NICE◇
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2016 (26/02/2016 EMA)
LONSURF®(一般名:トリフルリジン・チピラシル)が進行・再発の結腸・直腸がん治療薬として欧州で承認を取得- 欧州の患者さんに新たな治療選択肢を - (04/28/2016 大鵬薬品工業 Taiho Pharmaceutical)

<Medical Journal & Other News>
【乳がん/5-azacytidine/butyrate therapyで乳がん幹細胞を標的に】JOURNAL:Cancer Research
Two known chemotherapy agents effectively target breast cancer stem cells (05/02/2016 EurekAlert!/MEDICAL COLLEGE OF GEORGIA AT AUGUSTA UNIVERSITY)
AUGUSTA, Ga. - Two existing chemotherapy drugs appear to be a powerful pair in targeting errant stem cells that are making breast cancer and enabling its spread and recurrence, scientists report.A combination of the drugs, 5-azacytidine and the HDAC inhibitor butyrate, reduces the number of cancer stem cells and improves survival in an animal model of breast cancer, they report in the journal Cancer Research. Alone, neither was effective.

【欠陥のある現在の創薬方法に新アプローチ】JOURNAL:Nature Methods
Current cancer drug discovery method flawed: Study (05/02/2016 EurekAlert!/VANDERBILT UNIVERSITY MEDICAL CENTER)
The primary method used to test compounds for anti-cancer activity in cells is flawed, Vanderbilt University researchers report May 2 in Nature Methods. The findings cast doubt on methods used by the entire scientific enterprise and pharmaceutical industry to discover new cancer drugs."More than 90 percent of candidate cancer drugs fail in late stage clinical trials, costing hundreds of millions of dollars," said Vito Quaranta, M.D., director of the Quantitative Systems Biology Center at Vanderbilt. "The flawed in vitro drug discovery metric may not be the only responsible factor, but it may be worth pursuing an estimate of its impact."

Graphics 【日本国内:Japan】
「天皇陛下の癌」がん告知を主張した医師の遺書 初公開(1)(05/02/2016 デイリー新潮)
陛下にはがん告知はされていなかった がん告知を主張した医師の遺書 初公開(2)(05/02/2016 デイリー新潮)

ナノマシンを用いたがん治療 今年中には実現か? (05/02/2016 EconomicNews)

12人に1人がかかる乳がん 進行度、悪性度で治療法異なる (05/02/2016 NEWSポストセブン)

がん治療を阻む4つの誤解 偏った情報に惑わされ、正しい判断ができなくなることを避けるには 森山紀之ミッドタウンクリニック 理事 (05/01/2016 日経Goodday)

<雑誌記事:Magazine/Medical journal>
Stockholm Public Library
◆INNERVISION(インナービジョン) (2016年5月号)/インナービジョン/発売日:2016年5月1日/価格(税込):2,376円
【タイトル】特集 マルチモダリティによるAbdominal Imaging 2016
I 肝
1.肝細胞がんの診断  鶴﨑正勝ほか
2.早期肝細胞癌の診断  清水辰哉/本杉宇太郎
3.肝内胆管がんと肝転移の診断  藤田展宏ほか
4.肝良性腫瘤性病変の診断  小林 聡ほか
5.肝細胞がんのIVR治療  宮山士朗

II 胆 道
1.急性胆管炎の診断  小坂一斗ほか
2.胆道良性腫瘍の診断  五島 聡
3.胆道悪性腫瘍疾患の画像診断  牛尾貴輔ほか

III 膵 臓
1.膵悪性腫瘍の診断  望月健太郎ほか
2.膵良性腫瘍の診断  戸島史仁
3.膵嚢胞性腫瘍の診断  入江裕之ほか
4.慢性膵炎(自己免疫性膵炎を含む)の診断  藤永康成ほか

IV 腎・副腎
1.悪性腎腫瘍の診断  秋田大宇/陣崎雅弘
2.良性腎腫瘤および炎症性腎疾患の診断  吉田耕太郎ほか

◆NutritionCare(ニュートリションケア) (2016年5月号)/メディカ出版/発売日:2016年5月1日/価格(税込):1,944円
 大妻女子大学/島根大学 川口美喜子

◆エルネオス (ELNEOS) (2016年5月号)/エルネオス出版社/発売日:2016年5月1日/価格(税込):853円

◆モダンフィジシャン(Modern Physician) (2016年No.5)/新興医学出版社/発売日:2016年5月1日/価格(税込):3,024円
【タイトル】特集 価値に基づく医療―患者にとっての最善の選択をめざして
・17.価値に基づく医療の実践―がん診療(山内 英子)


◆医薬経済 (1515号)/医薬経済社/発売日:2016年5月1日/価格(税込):2,160円